Biotron expands HCV trial
Thursday, 14 August, 2008
Biotron [ASX: BIT] has expanded its Phase Ib/IIa clinical trial of its BIT225 hepatitis C treatment in an effort to maximise recruitment rates.
Testing will now be conducted at a Brisbane site in addition to the planned trial at a site in NSW.
The trial will be a placebo-controlled, randomised and multi-dose study examining the safety, pharmacokinetics and antiviral activity of the treatment.
The trial should be completed by the end of the year.
BIT225 targets the p7 protein of HCV, and has shown promising results in surrogate models of HCV infection.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
